AHA 2024 - Sanjit Jolly shares the spironolactone factorial results of the CLEAR SYNERGY (OASIS 9) trial, in which routine use of spironolactone did not reduce the risk of the two co-primary endpoints after an MI.
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
AHA 2024 - Sanjit Jolly shares the spironolactone factorial results of the CLEAR SYNERGY (OASIS 9) trial, in which routine use of spironolactone did not reduce the risk of the two co-primary endpoints after an MI.
This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.
Sanjit Jolly, MD is an interventional cardiologist at Hamilton Health Sciences and associate professor at McMaster University in Hamilton, ON, Canada.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
The findings of this study were simultaneously published in N Eng J Med.
Release date: 20 November 2024
AHA 2024 - Sanjit Jolly shares the spironolactone factorial results of the CLEAR SYNERGY (OASIS 9) trial, in which routine use of spironolactone did not reduce the risk of the two co-primary endpoints after an MI.
This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.
Sanjit Jolly, MD is an interventional cardiologist at Hamilton Health Sciences and associate professor at McMaster University in Hamilton, ON, Canada.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
The findings of this study were simultaneously published in N Eng J Med.
Release date: 20 November 2024
Stay current with the best on medical education
